Wall Street Zen Downgrades Creative Medical Technology (NASDAQ:CELZ) to Sell

Creative Medical Technology (NASDAQ:CELZ) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Creative Medical Technology in a research note on Monday. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce”.

Creative Medical Technology Price Performance

Shares of CELZ stock opened at $2.11 on Friday. The company has a market cap of $5.44 million, a price-to-earnings ratio of -0.73 and a beta of 2.06. Creative Medical Technology has a 1 year low of $1.69 and a 1 year high of $6.90. The firm has a fifty day moving average price of $3.01 and a 200-day moving average price of $2.99.

Creative Medical Technology (NASDAQ:CELZ) last announced its earnings results on Friday, November 7th. The company reported ($0.48) EPS for the quarter, hitting analysts’ consensus estimates of ($0.48). Equities research analysts expect that Creative Medical Technology will post -3.19 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Creative Medical Technology stock. Armistice Capital LLC acquired a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 148,000 shares of the company’s stock, valued at approximately $321,000. Armistice Capital LLC owned approximately 3.38% of Creative Medical Technology at the end of the most recent reporting period. Institutional investors own 1.42% of the company’s stock.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.